DK3031913T3 - Hidtil ukendt antistof mod humane tslp-receptorer - Google Patents

Hidtil ukendt antistof mod humane tslp-receptorer Download PDF

Info

Publication number
DK3031913T3
DK3031913T3 DK14833804.9T DK14833804T DK3031913T3 DK 3031913 T3 DK3031913 T3 DK 3031913T3 DK 14833804 T DK14833804 T DK 14833804T DK 3031913 T3 DK3031913 T3 DK 3031913T3
Authority
DK
Denmark
Prior art keywords
awesome
humane
disease
tslp receptors
tslp
Prior art date
Application number
DK14833804.9T
Other languages
English (en)
Inventor
Hiromu Sato
Daisuke Yamajuku
Kazunori Arai
Mako Ogino
Original Assignee
Astellas Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astellas Pharma Inc filed Critical Astellas Pharma Inc
Application granted granted Critical
Publication of DK3031913T3 publication Critical patent/DK3031913T3/da

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46Hybrid immunoglobulins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244Interleukins [IL]
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12PFERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00Preparation of peptides or proteins
    • C12P21/02Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/20Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/20Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/40Immunoglobulins specific features characterized by post-translational modification
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565Complementarity determining region [CDR]
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/90Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/30Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Pulmonology (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
DK14833804.9T 2013-08-09 2014-08-08 Hidtil ukendt antistof mod humane tslp-receptorer DK3031913T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2013165676 2013-08-09
PCT/JP2014/071008 WO2015020193A1 (ja) 2013-08-09 2014-08-08 新規抗ヒトtslp受容体抗体

Publications (1)

Publication Number Publication Date
DK3031913T3 true DK3031913T3 (da) 2019-05-20

Family

ID=52461517

Family Applications (1)

Application Number Title Priority Date Filing Date
DK14833804.9T DK3031913T3 (da) 2013-08-09 2014-08-08 Hidtil ukendt antistof mod humane tslp-receptorer

Country Status (29)

Country Link
US (2) US9328171B2 (da)
EP (1) EP3031913B1 (da)
JP (1) JP6380394B2 (da)
KR (1) KR102260680B1 (da)
AR (1) AR097293A1 (da)
AU (1) AU2014303356B2 (da)
BR (1) BR112016002743B1 (da)
CA (1) CA2920484C (da)
CY (1) CY1121678T1 (da)
DK (1) DK3031913T3 (da)
ES (1) ES2730978T3 (da)
HK (1) HK1223123A1 (da)
HR (1) HRP20190752T1 (da)
HU (1) HUE043111T2 (da)
IL (1) IL243851B (da)
LT (1) LT3031913T (da)
MX (1) MX369208B (da)
MY (1) MY177098A (da)
PH (1) PH12016500237B1 (da)
PL (1) PL3031913T3 (da)
PT (1) PT3031913T (da)
RS (1) RS58696B1 (da)
RU (1) RU2689528C2 (da)
SG (1) SG11201600935SA (da)
SI (1) SI3031913T1 (da)
TR (1) TR201906969T4 (da)
TW (1) TWI635097B (da)
UA (1) UA119328C2 (da)
WO (1) WO2015020193A1 (da)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2018007520A (es) * 2015-12-18 2018-08-01 Astellas Pharma Inc Composicion farmaceutica que comprende un anticuerpo receptor de linfopoyetina estromal timica antihumano.
KR20230035350A (ko) 2020-07-06 2023-03-13 플래그쉽 파이어니어링 이노베이션스 브이아이, 엘엘씨 SARS-CoV-2를 표적으로 하는 항원 결합 분자
IL300720A (en) 2020-08-26 2023-04-01 Flagship Pioneering Innovations Vi Llc Antigen binding molecules targeting Sars-cov-2
CN114853888B (zh) * 2021-02-05 2023-11-03 上海洛启生物医药技术有限公司 抗tslp纳米抗体及其应用
CN113069543B (zh) * 2021-06-07 2021-08-06 迈威(上海)生物科技股份有限公司 包含抗胸腺基质淋巴细胞生成素的单克隆抗体的液体组合物
WO2023028612A2 (en) * 2021-08-27 2023-03-02 Board Of Regents, The University Of Texas System Anti-tslpr (crlf2) antibodies
CN114028562B (zh) * 2021-11-01 2022-05-24 江苏荃信生物医药股份有限公司 包含抗人胸腺基质淋巴细胞生成素(tslp)单克隆抗体的液体制剂
CN117209603B (zh) * 2021-12-02 2024-02-27 北京东方百泰生物科技股份有限公司 一种抗tslp的单克隆抗体、其抗原结合片段及其应用
CN116217725B (zh) * 2021-12-02 2023-09-22 北京东方百泰生物科技股份有限公司 一种抗tslp单克隆抗体的纯化方法
US11993644B2 (en) 2022-05-06 2024-05-28 Generate Biomedicines, Inc. Antigen binding molecules targeting SARS-CoV-2
US20240173405A1 (en) * 2022-11-07 2024-05-30 Upstream Bio, Inc. Pharmaceutical compositions comprising anti-human tslp receptor antibodies and methods of using the same

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
ATE256751T1 (de) 1993-03-11 2004-01-15 Chemo Sero Therapeut Res Inst Monoklonaler anti-hiv antikörper
PT2077279E (pt) * 2000-06-28 2012-09-14 Amgen Inc Moléculas do receptor de linfopoietina estromal tímica e suas utilizações
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
US20050249712A1 (en) * 2004-03-23 2005-11-10 The Government Of The Usa As Represented By The Secretary Of The Dept. Of Health & Human Services Methods for use of TSLP and agonists and antagonists thereof
PE20081186A1 (es) * 2006-01-13 2008-09-24 Irm Llc Metodos y composiciones para el tratamiento de enfermedades alergicas
UA95329C2 (ru) * 2006-12-14 2011-07-25 Шеринг-Плау Лтд. Собачий тимусный стромальный лимфопоэтин и его применение
JP2010530233A (ja) * 2007-06-20 2010-09-09 アイアールエム・リミテッド・ライアビリティ・カンパニー アレルギー疾患を処置する方法および組成物
CN101986784A (zh) 2008-02-07 2011-03-16 先灵公司 基因工程tslpr抗体
TW201201840A (en) * 2010-07-15 2012-01-16 Hoffmann La Roche Antibodies specifically binding to human TSLPR and methods of use
WO2012015696A1 (en) * 2010-07-26 2012-02-02 Baylor Research Institute Thymic stromal lymphopoietin (tslp) and ox40 ligand in cancer
EP2773774A4 (en) * 2011-11-03 2015-06-10 Merck Sharp & Dohme BIOMARKERS FOR THE TREATMENT OF TSLP

Also Published As

Publication number Publication date
RU2016107814A3 (da) 2018-06-28
PL3031913T3 (pl) 2019-08-30
EP3031913B1 (en) 2019-04-17
TR201906969T4 (tr) 2019-06-21
US9328171B2 (en) 2016-05-03
PH12016500237A1 (en) 2016-05-02
IL243851A0 (en) 2016-04-21
MX2016001796A (es) 2016-04-15
SG11201600935SA (en) 2016-03-30
TWI635097B (zh) 2018-09-11
JPWO2015020193A1 (ja) 2017-03-02
KR102260680B1 (ko) 2021-06-07
CA2920484C (en) 2021-03-30
AR097293A1 (es) 2016-03-02
TW201536806A (zh) 2015-10-01
BR112016002743B1 (pt) 2020-12-08
RS58696B1 (sr) 2019-06-28
HK1223123A1 (zh) 2017-07-21
CY1121678T1 (el) 2020-07-31
US20160046720A1 (en) 2016-02-18
ES2730978T3 (es) 2019-11-13
UA119328C2 (uk) 2019-06-10
US9908941B2 (en) 2018-03-06
WO2015020193A1 (ja) 2015-02-12
MY177098A (en) 2020-09-05
RU2689528C2 (ru) 2019-05-28
HRP20190752T1 (hr) 2019-06-14
AU2014303356A1 (en) 2016-02-18
HUE043111T2 (hu) 2019-08-28
PT3031913T (pt) 2019-05-31
KR20160035080A (ko) 2016-03-30
CA2920484A1 (en) 2015-02-12
IL243851B (en) 2019-11-28
JP6380394B2 (ja) 2018-08-29
AU2014303356B2 (en) 2020-01-02
EP3031913A1 (en) 2016-06-15
SI3031913T1 (sl) 2019-06-28
PH12016500237B1 (en) 2016-05-02
LT3031913T (lt) 2019-05-27
RU2016107814A (ru) 2017-09-14
US20160208005A1 (en) 2016-07-21
MX369208B (es) 2019-10-31
EP3031913A4 (en) 2017-03-22
BR112016002743A2 (pt) 2017-11-21
AU2014303356A2 (en) 2017-02-02

Similar Documents

Publication Publication Date Title
DK3031913T3 (da) Hidtil ukendt antistof mod humane tslp-receptorer
DK3083694T3 (da) Caniniserede, murine anti-canin-pd-1-antistoffer
DE102013107115B8 (de) Schalldämpfer
DK3030581T3 (da) Antistofbindingssteder, der er specifikke for egfrviii
DK3090171T3 (da) Forbedringer relateret til komponenthåndtering, særligt vindmøllekomponenthåndtering
DK2975030T3 (da) Dihydropyridazin-3,5-dion-derivat
DK3080385T3 (da) Forbedret lukkeapparat
ITPG20130023U1 (it) Emulatore elettroiniettori carburante
TH1301005663B (th) เครื่องยนต์
UA26572S (uk) Двигун
UA27458S (uk) Подушка двигуна
UA27459S (uk) Подушка двигуна
UA27445S (uk) Подушка двигуна
FI20135658A (fi) Äänenvaimennuselementti
ITRM20130618A1 (it) Nuove composizioni.
ITRM20130616A1 (it) Nuove composizioni.
UA26579S (uk) Підвіска глушника
UA26865S (uk) Колінчастий вал
TH1301005664B (th) เครื่องยนต์
TH1301005662B (th) เครื่องยนต์
UA25369S (uk) Вал колінчатий
UA25371S (uk) Вал колінчатий
UA25577S (uk) Вал колінчастий
UA25673S (uk) Вал колінчастий
UA26414S (uk) Поршень